Infant Bacterial Therapeutics (IBT-B.ST) Stock Analysis & AI Equity Report
Infant Bacterial Therapeutics (IBT-B.ST) overview
Infant Bacterial Therapeutics (IBT-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Infant Bacterial Therapeutics reported revenue of SEK 0.0m and operating profit of SEK -140m; the year-end share price was 53.60 SEK and market capitalisation was SEK 722m. Infant Bacterial Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Infant Bacterial Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB is a pharmaceutical company developing and commercializing medicines for diseases affecting premature infants. Its lead program, IBP-9414, is a bacterial strain-based drug candidate designed to prevent necrotizing enterocolitis and support gastrointestinal function. The company also advances additional candidates for gastroschisis, retinopathy of prematurity, and antibiotic-resistant hospital infections.
Generate the Infant Bacterial Therapeutics report
Infant Bacterial Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Infant Bacterial Therapeutics and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.